|
2
|
Martsevich SY, Lukina YV, Kutishenko NP, Guseynova ET. 0Effects of the COVID-19 Pandemic on Treatment Adherence in Patients with Chronic Heart Failure. CASPIAN JOURNAL OF INTERNAL MEDICINE 2022; 13:199-203. [PMID: 35872693 PMCID: PMC9272958 DOI: 10.22088/cjim.13.0.199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 08/08/2021] [Accepted: 09/11/2021] [Indexed: 11/01/2022]
Abstract
Background To assess the influence of the COVID-19 (Coronavirus Disease 2019) pandemic on treatment adherence by patients with CHF (Chronic heart failure) and to determine the factors associated with changing adherence during home-isolation. Methods The survey was conducted in patients participating in the COMPLIANCE study (ClinicalTrials.gov. NCT04262583). Thirty-one patients, included into in the COMPLIANCE study before March 1, 2020, were interviewed through phone calls. A modified adherence scale of the National Society for Evidence-Based Pharmacotherapy was used, which permits to assess of overall adherence, adherence to particular drugs and the main causes for non-adherence. Results In the whole group of patients, only a tendency to reduced overall adherence was registered during the COVID-19 pandemic (р=0,256). Significant differences in the rate of adherence deterioration were revealed for angiotensin-converting enzyme (ACE) inhibitors (p=0.031) and for statins (p=0.002). The reasons for non-adherence were lack of opportunity to contact with a physician, inability to perform investigations necessary for correcting prescribed pharmacotherapy, and side effects. Conclusion A tendency to deterioration of adherence to prescribed pharmacotherapy was revealed during the COVID-19 pandemic. A significant decline in adherence was registered to ACE inhibitors and statins.
Collapse
Affiliation(s)
- Sergey Yu. Martsevich
- Department of Preventive Pharmacotherapy, National Medical Research Center for Therapy and Preventive Medicine, Petroverigsky per. 10, Moscow, Russia
| | - Yulia V. Lukina
- Department of Preventive Pharmacotherapy, National Medical Research Center for Therapy and Preventive Medicine, Petroverigsky per. 10, Moscow, Russia
| | - Natalia P. Kutishenko
- Department of Preventive Pharmacotherapy, National Medical Research Center for Therapy and Preventive Medicine, Petroverigsky per. 10, Moscow, Russia
| | - Elmira T. Guseynova
- Department of Preventive Pharmacotherapy, National Medical Research Center for Therapy and Preventive Medicine, Petroverigsky per. 10, Moscow, Russia
| |
Collapse
|
|
3
|
Bertani L, Barberio B, Tricò D, Zanzi F, Maniero D, Ceccarelli L, Marsilio I, Coppini F, Lorenzon G, Mumolo MG, Zingone F, Costa F, Savarino EV. Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak. J Clin Med 2021; 10:jcm10153270. [PMID: 34362053 PMCID: PMC8348517 DOI: 10.3390/jcm10153270] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 07/20/2021] [Accepted: 07/21/2021] [Indexed: 12/11/2022] Open
Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, immunomodulatory therapies and hospital admission were suspected to increase the risk of infection. Nevertheless, patients with inflammatory bowel diseases (IBD) treated with intravenous (i.v.) biologics had to move to hospitals for drug infusion. We investigated the impact of hospitalisation in patients with IBD. We conducted a survey including consecutive IBD patients initially in clinical and biochemical remission treated with biologics at the end of the first lockdown period. Patients underwent the normally scheduled clinical visits, performed at hospital for i.v.-treated patients or at home for patients treated with s.c. drugs. We administered to all patients the Hospital Anxiety and Depression Scale (HADS) questionnaire and other 12 questions, specifically related to COVID-19 and its implications. A total of 189 IBD patients were recruited, 112 (59.3%) treated with i.v. drugs and 77 (40.7%) with s.c. ones. No relapses were recorded in either group (hospitalized vs. non-hospitalized, p = ns), as well as which, COVID-19 infections were not demonstrated in patients in contact with people with suspected symptoms or directly experiencing them. The total HADS score obtained by the sum of all items was also almost identical between groups (37.1 ± 2.8 vs. 37.2 ± 2.8; p = 0.98). In patients treated with i.v. drugs receiving a televisit (n = 17), the rate of satisfaction with telemedicine (58.8%) was significantly lower compared with those treated with s.c. drugs (94.8%; p < 0.0005). Our results suggest that hospitalisation during the COVID-19 outbreak does not increase the risk of COVID-19 infection as well as the risk of IBD relapse; moreover, the similar levels of anxiety in both groups could confirm that there is no need to convert patients from i.v. to s.c. therapy.
Collapse
Affiliation(s)
- Lorenzo Bertani
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56100 Pisa, Italy; (F.Z.); (F.C.)
- Department of Surgery, Tuscany North-West ASL, Massa Apuane Hospital, 54100 Massa, Italy
- Correspondence:
| | - Brigida Barberio
- Department of Surgery, Oncology and Gastroenterology, DISCOG, University of Padua, 35100 Padua, Italy; (B.B.); (D.M.); (I.M.); (G.L.); (F.Z.); (E.V.S.)
| | - Domenico Tricò
- Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, 56100 Pisa, Italy;
| | - Federico Zanzi
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56100 Pisa, Italy; (F.Z.); (F.C.)
| | - Daria Maniero
- Department of Surgery, Oncology and Gastroenterology, DISCOG, University of Padua, 35100 Padua, Italy; (B.B.); (D.M.); (I.M.); (G.L.); (F.Z.); (E.V.S.)
| | - Linda Ceccarelli
- Department of General Surgery and Gastroenterology, IBD Unit, Pisa University Hospital, 56124 Pisa, Italy; (L.C.); (M.G.M.); (F.C.)
| | - Ilaria Marsilio
- Department of Surgery, Oncology and Gastroenterology, DISCOG, University of Padua, 35100 Padua, Italy; (B.B.); (D.M.); (I.M.); (G.L.); (F.Z.); (E.V.S.)
| | - Francesca Coppini
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56100 Pisa, Italy; (F.Z.); (F.C.)
| | - Greta Lorenzon
- Department of Surgery, Oncology and Gastroenterology, DISCOG, University of Padua, 35100 Padua, Italy; (B.B.); (D.M.); (I.M.); (G.L.); (F.Z.); (E.V.S.)
| | - Maria Gloria Mumolo
- Department of General Surgery and Gastroenterology, IBD Unit, Pisa University Hospital, 56124 Pisa, Italy; (L.C.); (M.G.M.); (F.C.)
| | - Fabiana Zingone
- Department of Surgery, Oncology and Gastroenterology, DISCOG, University of Padua, 35100 Padua, Italy; (B.B.); (D.M.); (I.M.); (G.L.); (F.Z.); (E.V.S.)
| | - Francesco Costa
- Department of General Surgery and Gastroenterology, IBD Unit, Pisa University Hospital, 56124 Pisa, Italy; (L.C.); (M.G.M.); (F.C.)
| | - Edoardo Vincenzo Savarino
- Department of Surgery, Oncology and Gastroenterology, DISCOG, University of Padua, 35100 Padua, Italy; (B.B.); (D.M.); (I.M.); (G.L.); (F.Z.); (E.V.S.)
| |
Collapse
|